Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura
Top Cited Papers
Open Access
- 1 June 2004
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 103 (11), 4043-4049
- https://doi.org/10.1182/blood-2003-11-4035
Abstract
Therapeutic plasma exchange is an effective empiric treatment for thrombotic thrombocytopenic purpura (TTP), but how therapy affects the level of adisKeywords
This publication has 58 references indexed in Scilit:
- Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13Blood, 2004
- Nonneutralizing IgM and IgG antibodies to von Willebrand factor–cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpuraBlood, 2003
- Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndromeBlood, 2003
- Cleavage of von Willebrand Factor Requires the Spacer Domain of the Metalloprotease ADAMTS13Journal of Biological Chemistry, 2003
- Mutation analysis and clinical implications of von Willebrand factor–cleaving protease deficiencyKidney International, 2003
- von Willebrand factor cleaving protease and ADAMTS13mutations in childhood TTPBlood, 2003
- Thrombotic Thrombocytopenic Purpura Following Stem Cell TransplantationLeukemia & Lymphoma, 2002
- Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving proteaseBest Practice & Research Clinical Haematology, 2001
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982
- THROMBOTIC THROMBOCYTOPENIC PURPURAMedicine, 1966